Iptacopan is an orally active small-molecule inhibitor of complement factor B, a key component of the alternative pathway of the complement system. By selectively inhibiting factor B, iptacopan suppresses alternative-pathway complement activation and downstream complement-mediated inflammation and tissue injury.
Iptacopan is used in approved indications involving complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy (C3G) in applicable patient populations.
Iptacopan is a specialized pharmaceutical API requiring controlled chemical synthesis, purification and comprehensive analytical characterization.
Quality evaluation may include identity, assay, related substances, residual solvents, water content, elemental impurities, polymorphic form, particle-size distribution and stability-related impurities.
CAS Number: 2171015-78-2
Molecular Formula: C25H31F2N5O2
Molecular Weight: 471.55 g/mol
Chemical Name: Iptacopan
Drug Class: Complement Inhibitor
Pharmacological Class: Complement Factor B Inhibitor
Therapeutic Class: Immunomodulatory Agent
Therapeutic Area: Hematology / Nephrology / Immunology
Iptacopan selectively inhibits complement factor B, which is required for activation of the alternative complement pathway.
By inhibiting factor B, iptacopan reduces formation and activity of the alternative-pathway C3 convertase, thereby decreasing downstream complement activation.
This can reduce complement-mediated:
Iptacopan is used in the management of selected complement-mediated disorders, including:
Its indication and patient eligibility depend on the applicable regulatory authorization and approved product labeling.
The complement system is an important component of innate immunity. Dysregulated alternative-pathway activation can contribute to hemolysis, inflammation and tissue damage.
Unlike terminal complement inhibitors that primarily target downstream components, iptacopan acts upstream at factor B, providing selective inhibition of the alternative complement pathway.
Iptacopan is a synthetic, fluorinated small molecule containing nitrogen and oxygen functional groups. Its physicochemical characteristics are relevant to formulation development, solid-state characterization and oral drug-product development.
Typical API manufacturing may involve:
Iptacopan API quality evaluation may include:
Iptacopan should be stored in a tightly closed container under controlled pharmaceutical conditions, protected from excessive heat, moisture and direct light. Final storage requirements should follow validated stability data.
Iptacopan is relevant to research involving:
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 2.0% |
| Water Content | NMT 1.0% |